127 related articles for article (PubMed ID: 38630892)
1. Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-cell Lymphoma.
Meriranta L; Sorri S; Huse K; Liu X; Spasevska I; Zafar S; Chowdhury I; Dufva O; Sahlberg E; Tandaric L; Karjalainen-Lindsberg ML; Hyytiainen M; Varjosalo M; Myklebust JH; Leppa S
Blood Cancer Discov; 2024 Apr; ():. PubMed ID: 38630892
[TBL] [Abstract][Full Text] [Related]
2. Loss of KLHL6 promotes diffuse large B-cell lymphoma growth and survival by stabilizing the mRNA decay factor roquin2.
Choi J; Lee K; Ingvarsdottir K; Bonasio R; Saraf A; Florens L; Washburn MP; Tadros S; Green MR; Busino L
Nat Cell Biol; 2018 May; 20(5):586-596. PubMed ID: 29695787
[TBL] [Abstract][Full Text] [Related]
3. KLHL6 is a tumor suppressor gene in diffuse large B-cell lymphoma.
Choi J; Zhou N; Busino L
Cell Cycle; 2019 Feb; 18(3):249-256. PubMed ID: 30646831
[TBL] [Abstract][Full Text] [Related]
4. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.
Davis RE; Ngo VN; Lenz G; Tolar P; Young RM; Romesser PB; Kohlhammer H; Lamy L; Zhao H; Yang Y; Xu W; Shaffer AL; Wright G; Xiao W; Powell J; Jiang JK; Thomas CJ; Rosenwald A; Ott G; Muller-Hermelink HK; Gascoyne RD; Connors JM; Johnson NA; Rimsza LM; Campo E; Jaffe ES; Wilson WH; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Pierce SK; Staudt LM
Nature; 2010 Jan; 463(7277):88-92. PubMed ID: 20054396
[TBL] [Abstract][Full Text] [Related]
5. Differential expression of Toll-like receptor (TLR) and B cell receptor (BCR) signaling molecules in primary diffuse large B-cell lymphoma of the central nervous system.
Akhter A; Masir N; Elyamany G; Phang KC; Mahe E; Al-Zahrani AM; Shabani-Rad MT; Stewart DA; Mansoor A
J Neurooncol; 2015 Jan; 121(2):289-96. PubMed ID: 25391967
[TBL] [Abstract][Full Text] [Related]
6. The BTB-kelch protein KLHL6 is involved in B-lymphocyte antigen receptor signaling and germinal center formation.
Kroll J; Shi X; Caprioli A; Liu HH; Waskow C; Lin KM; Miyazaki T; Rodewald HR; Sato TN
Mol Cell Biol; 2005 Oct; 25(19):8531-40. PubMed ID: 16166635
[TBL] [Abstract][Full Text] [Related]
7. Klhl6 Deficiency Impairs Transitional B Cell Survival and Differentiation.
Bertocci B; Lecoeuche D; Sterlin D; Kühn J; Gaillard B; De Smet A; Lembo F; Bole-Feysot C; Cagnard N; Fadeev T; Dahan A; Weill JC; Reynaud CA
J Immunol; 2017 Oct; 199(7):2408-2420. PubMed ID: 28807996
[TBL] [Abstract][Full Text] [Related]
8. Expression, purification, and microscopic characterization of the tumor suppressor KLHL6.
Han L; Chen Z; Sun L
Protein Expr Purif; 2023 Oct; 210():106318. PubMed ID: 37286065
[TBL] [Abstract][Full Text] [Related]
9. MYD88
Chen R; Zhou D; Wang L; Zhu L; Ye X
Ther Adv Hematol; 2022; 13():20406207211072839. PubMed ID: 35126963
[TBL] [Abstract][Full Text] [Related]
10. MYD88L265P augments proximal B-cell receptor signaling in large B-cell lymphomas via an interaction with DOCK8.
Mandato E; Yan Q; Ouyang J; Paczkowska J; Qin Y; Hao Y; Bojarczuk K; Hansen J; Chapuy B; Rodig SJ; Khan SJ; Redd RA; Shipp MA
Blood; 2023 Oct; 142(14):1219-1232. PubMed ID: 37467575
[TBL] [Abstract][Full Text] [Related]
11. Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B Cell Lymphoma.
Corcoran SR; Phelan JD; Choi J; Shevchenko G; Fenner RE; Yu X; Scheich S; Hsiao T; Morris VM; Papachristou EK; Kishore K; D'Santos CS; Ji Y; Pittaluga S; Wright GW; Urlaub H; Pan KT; Oellerich T; Muppidi J; Hodson DJ; Staudt LM
Cancer Discov; 2024 Apr; ():. PubMed ID: 38683128
[TBL] [Abstract][Full Text] [Related]
12. DLBCL-associated NOTCH2 mutations escape ubiquitin-dependent degradation and promote chemoresistance.
Zhou N; Choi J; Grothusen G; Kim BJ; Ren D; Cao Z; Liu Y; Li Q; Inamdar A; Beer T; Tang HY; Perkey E; Maillard I; Bonasio R; Shi J; Ruella M; Wan L; Busino L
Blood; 2023 Sep; 142(11):973-988. PubMed ID: 37235754
[TBL] [Abstract][Full Text] [Related]
13. B-Cell Receptor Signaling and Beyond: The Role of Igα (CD79a)/Igβ (CD79b) in Normal and Malignant B Cells.
Tkachenko A; Kupcova K; Havranek O
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203179
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic Mutations of MYD88 and CD79B in Diffuse Large B-Cell Lymphoma and Implications for Clinical Practice.
Visco C; Tanasi I; Quaglia FM; Ferrarini I; Fraenza C; Krampera M
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33050534
[TBL] [Abstract][Full Text] [Related]
15. A multiprotein supercomplex controlling oncogenic signalling in lymphoma.
Phelan JD; Young RM; Webster DE; Roulland S; Wright GW; Kasbekar M; Shaffer AL; Ceribelli M; Wang JQ; Schmitz R; Nakagawa M; Bachy E; Huang DW; Ji Y; Chen L; Yang Y; Zhao H; Yu X; Xu W; Palisoc MM; Valadez RR; Davies-Hill T; Wilson WH; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Delabie J; Rimsza LM; Rodriguez FJ; Estephan F; Holdhoff M; Kruhlak MJ; Hewitt SM; Thomas CJ; Pittaluga S; Oellerich T; Staudt LM
Nature; 2018 Aug; 560(7718):387-391. PubMed ID: 29925955
[TBL] [Abstract][Full Text] [Related]
16. MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma.
Takeuchi T; Yamaguchi M; Kobayashi K; Miyazaki K; Tawara I; Imai H; Ono R; Nosaka T; Tanaka K; Katayama N
Cancer; 2017 Apr; 123(7):1166-1173. PubMed ID: 27915469
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of CD79A and CD79B Support for IgM+ B Cell Fitness through B Cell Receptor Surface Expression.
Huse K; Bai B; Hilden VI; Bollum LK; Våtsveen TK; Munthe LA; Smeland EB; Irish JM; Wälchli S; Myklebust JH
J Immunol; 2022 Nov; 209(10):2042-2053. PubMed ID: 36426942
[TBL] [Abstract][Full Text] [Related]
18. Identification of unique molecular heterogeneity of human CD79, the signaling component of the human B cell antigen receptor (BCR), and synergistic potentiation of the CD79-targeted therapy of B cell tumors by co-targeting of CD79a and CD79b.
Seon BK; Okazaki M; Duzen J; Matsuno F; Goey AKL; Maguire O
Leuk Res; 2024 Jan; 136():107436. PubMed ID: 38232613
[TBL] [Abstract][Full Text] [Related]
19. Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.
Myklebust JH; Brody J; Kohrt HE; Kolstad A; Czerwinski DK; Wälchli S; Green MR; Trøen G; Liestøl K; Beiske K; Houot R; Delabie J; Alizadeh AA; Irish JM; Levy R
Blood; 2017 Feb; 129(6):759-770. PubMed ID: 28011673
[TBL] [Abstract][Full Text] [Related]
20. Tonic B-cell receptor signaling in diffuse large B-cell lymphoma.
Havranek O; Xu J; Köhrer S; Wang Z; Becker L; Comer JM; Henderson J; Ma W; Man Chun Ma J; Westin JR; Ghosh D; Shinners N; Sun L; Yi AF; Karri AR; Burger JA; Zal T; Davis RE
Blood; 2017 Aug; 130(8):995-1006. PubMed ID: 28646116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
